Drugs / HS-20105
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT06144723 | Mar 2024 → Mar 2026 overdue | neoplasm | Hansoh BioMedical R&D Company | Not yet recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | HS-20105 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06144723 ↗ |
| Route | Intravenous | “Administered intravenously every 21 days.” NCT06144723 ↗ |